TriangleNCT00887198 · OUTCOME
Time to Opiate Use for Prostate Cancer Pain
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization (Day 1) up to first opiate use or end of study (Month 60)
What was measured
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.
Analysis population: ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.
Groups in this outcome
Abiraterone Acetate + Prednisone (AAP)
Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
Placebo
Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
| Group | Source count |
|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 546 |
| Placebo | 542 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Abiraterone Acetate + Prednisone (AAP) | 33.38 | Not reported | 30.23 | 39.75 | Not reported |
| Placebo | 23.39 | Not reported | 20.27 | 27.53 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 30.23
- upper Limit
- 39.75
- value
- 33.38
- group Id
- OG001
- lower Limit
- 20.27
- upper Limit
- 27.53
- value
- 23.39
- denoms
- counts
- group Id
- OG000
- value
- 546
- group Id
- OG001
- value
- 542
- units
- Participants
- description
- The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- OG000
- title
- Abiraterone Acetate + Prednisone (AAP)
- description
- Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.
- id
- OG001
- title
- Placebo
- param Type
- MEDIAN
- population Description
- ITT population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.
- reporting Status
- POSTED
- time Frame
- From randomization (Day 1) up to first opiate use or end of study (Month 60)
- title
- Time to Opiate Use for Prostate Cancer Pain
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice